Protocol Ledger

NCT06335303 · Phase II · COMPLETED

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase II clinical trial protocol NCT06335303 sponsored by Boehringer Ingelheim in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-05 Enrollment: 322 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06335303
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)322 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06335303
Protocol FieldVerified Registry Value
NCT IdentifierNCT06335303
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment322 participants (ACTUAL)
Registered Start Date2024-09-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06335303
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI